In the management of adhesive small bowel obstruction (ASBO), the EAST Practice Management Guidelines recommend a water-soluble contrast (gastrografin) challenge. Which outcome defines 'success' and what is the therapeutic benefit of gastrografin beyond diagnosis?
- A Contrast reaching the large bowel within 24 hours predicts non-operative resolution; gastrografin has no direct therapeutic effect
- B Contrast failure to progress beyond the obstruction within 4 hours mandates emergency surgery
- C Gastrografin is used only for diagnosis; its osmotic properties are negligible in the bowel
- D Contrast reaching the colon within 24 hours predicts resolution AND gastrografin acts as an osmotic agent stimulating gut motility, reducing time to resolution and need for surgery ✓
Explanation
The water-soluble contrast challenge (gastrografin) has dual utility in ASBO: diagnostically, contrast reaching the colon within 24 hours (some protocols: 4 hours) predicts non-operative resolution with sensitivity ~97% and specificity ~96%, thereby identifying patients who will not need surgery. Therapeutically, gastrografin's high osmolarity (1900 mOsm/kg) draws fluid into the bowel lumen, reducing mucosal oedema, stimulating peristalsis, and directly contributing to obstruction resolution. Multiple RCTs and meta-analyses show gastrografin reduces time to bowel function recovery and reduces the operative rate compared to conservative management alone.
Reference: Bailey & Love's Short Practice of Surgery, 27th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.